Bioventus (NASDAQ:BVS) Now Covered by Analysts at CJS Securities

CJS Securities started coverage on shares of Bioventus (NASDAQ:BVS) in a report published on Friday morning, MarketBeat.com reports. The firm issued a market outperform rating and a $14.00 target price on the stock.

BVS has been the subject of a number of other research reports. Craig Hallum boosted their price target on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Finally, Barrington Research upped their target price on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $14.00.

Bioventus Trading Down 3.5%

Shares of BVS opened at $8.94 on Friday. Bioventus has a 1-year low of $5.81 and a 1-year high of $9.56. The company has a 50-day moving average of $8.49 and a 200 day moving average of $7.66. The firm has a market capitalization of $743.36 million, a price-to-earnings ratio of 27.09 and a beta of 0.78. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.02. The company had revenue of $157.90 million during the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Buying and Selling at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This represents a 21.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.00% of the company’s stock.

Hedge Funds Weigh In On Bioventus

Several institutional investors have recently bought and sold shares of BVS. Marshall Wace LLP lifted its position in shares of Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after buying an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after buying an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after acquiring an additional 1,887 shares in the last quarter. Deutsche Bank AG lifted its position in Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after acquiring an additional 1,908 shares during the last quarter. Finally, Covestor Ltd lifted its position in Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after acquiring an additional 2,176 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.